Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Chiron Charts. Click Here for more Chiron Charts.](/p.php?pid=staticchart&s=N%5ECHIR&p=8&t=15)
Chiron Names David Smith CFO
EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Chiron Corporation today
announced the appointment of David Smith, 44, to the position of chief financial
officer, effective immediately. Mr. Smith had been serving as Chiron's interim
chief financial officer while continuing in his role as vice president of
finance and principal accounting officer. He will continue to report to Howard
Pien, Chiron's president and chief executive officer, as well as continue to
serve as a member of Chiron's executive committee.
"David is a talented individual, and he has been a key contributor to Chiron's
continued success as the company executes on multiple growth and investment
initiatives in our blood testing, vaccines and biopharma businesses," said Mr.
Pien. "Over the last five years, David has strengthened our financial
operations, overseen the financial integration of recent acquisitions and led
internal initiatives that ensure robust compliance with new regulations under
Sarbanes-Oxley. We look forward to continued success under David's
leadership."
Mr. Smith joined Chiron Corporation as vice president, corporate controller, in
February 1999. Prior to joining Chiron, he served as vice president, finance,
and chief financial officer of Anergen, Inc. Prior to that, Mr. Smith held a
variety of finance positions with increasing levels of responsibility at
Genentech, including an international assignment in Europe. Mr. Smith is an
active member of Financial Executives International, where he serves on the
executive committee of the committee on corporate reporting.
About Chiron
Chiron Corporation, headquartered in Emeryville, California, is a global
pharmaceutical company that leverages a diverse business model to develop and
commercialize high-value products that make a difference in people's lives. The
company has a strategic focus on cancer and infectious disease. Chiron applies
its advanced understanding of the biology of cancer and infectious disease to
develop products from its platforms in proteins, small molecules and vaccines.
The company commercializes its products through three business units:
BioPharmaceuticals, Vaccines and Blood Testing. For more information about
Chiron, visit the company's website at http://www.chiron.com/.
This news release contains forward-looking statements that involve risks and
uncertainties and are subject to change. A full discussion of the company's
operations and financial condition, including factors that may affect its
business and future prospects, is contained in documents the company has filed
with the SEC, including the form 10-Q for the quarter ended June 30, 2003, and
the form 10-K for the year ended December 31, 2002, and will be contained in all
subsequent periodic filings made with the SEC.
Consistent with SEC Regulation FD, we do not undertake an obligation to update
the forward-looking information we are giving today.
DATASOURCE: Chiron Corporation
CONTACT: Chiron Corporate Communications & Investor Relations, Media:
+1-510-923-6500, or Investors: +1-510-923-2300
Web site: http://www.chiron.com/